Eye movement quantitative evaluation before and after high-dose 6-methylprednisolone in multiple sclerosis

Area of Science:

• Neuroscience
• Ophthalmology
• Neurology

Background:

• Multiple sclerosis (MS) is a demyelinating disease affecting the central nervous system.
• Ocular motor dysfunction, including saccadic and smooth pursuit eye movements, is common in MS patients.
• Evaluating the impact of treatment on these specific neurological functions is crucial for understanding disease progression and therapeutic efficacy.

Purpose of the Study:

• To quantitatively assess saccadic and smooth pursuit eye movements in multiple sclerosis patients during disease worsening.
• To evaluate the effects of high-dose 6-methylprednisolone infusions on ocular motor parameters.
• To investigate the correlation between neurophysiological changes in eye movements and clinical status.

Main Methods:

• Studied 24 multiple sclerosis patients during disease exacerbation.
• Performed quantitative analysis of saccadic eye movements (amplitude/duration, amplitude/peak velocity, precision, latency).
• Assessed smooth pursuit eye movements using the target velocity/performance index relationship before and after 6-methylprednisolone treatment.

Main Results:

• At baseline, 91.7% of patients displayed at least one ocular motor abnormality.
• Following treatment, 45.8% of patients showed modifications in one or more eye movement parameters.
• Latency improvement was the sole statistically significant group modification; neurophysiological changes did not correlate with clinical improvements.

Conclusions:

• Saccadic and smooth pursuit eye movements are frequently impaired in multiple sclerosis patients.
• High-dose 6-methylprednisolone treatment can lead to some improvements in ocular motor function, particularly saccadic latency.
• Observed neurophysiological changes in eye movements do not reliably reflect clinical disease status in multiple sclerosis.